New opportunities in treatment of polycystic ovary syndrome
https://doi.org/10.33667/2078-5631-2022-4-27-30
Abstract
Aim. To analyze the efficiency of the use of inosit in the treatment of polycystic ovary syndrome (PCOS) in women of reproductive age.
Materials and methods. The prospective study included 80 patients aged 21 to 35 years with a diagnosis of PCOS. The main group consisted of 45 women who were prescribed inosit and lifestyle modification to correct symptoms of PCOS. The control group consisted of 35 women for whom was recommended only lifestyle modification. The condition of the patients was assessed at the beginning of therapy, after 3 and 6 months.
Results. During therapy, the patients of the main group showed a statistically significant effect of inosit on metabolic status: a decrease in fasting glucose and insulin levels, body mass index; hormonal status: a decrease in the level of androstenedione, testosterone, LH, normalization of the LH/FSH, a decrease in the clinical manifestations of hyperandrogenism; restored menstrual cycle with ovulation
Conclusions. The use of inosit along with a balanced diet and physical activity is an effective means for correcting clinical manifestations and improving the quality of life of women with PCOS.
About the Authors
A. B. Khuraseva
Kursk State Medical University
Russian Federation
Russian Federation
Khuraseva Anna B., MD, professor at Dept of Obstetrics and Gynecology of Institute of Continuing Education
Kursk
SPIN: 5905–9909,
Researcher ID: ААВ 6828–2020
K. S. Svyatchenko
Medical Centre ‘Zhivitsa’
Russian Federation
Russian Federation
Svyatchenko Ksenia S., obstetrician-gynecologist
Kursk
SPIN: 5905–9909бб,
Researcher ID: ААВ 6828–2020
I. N. Medvedev
Kursk State Medical University;
Medical Centre ‘Zhivitsa’
Russian Federation
Russian Federation
Medvedevа Irina N., PhD Med, associate professor at Dept of Obstetrics and Gynecology of Institute of Continuing Education1, obstetrician-gynecologist
Kursk
SPIN: 5905–9909б
Researcher ID: ААВ 6828–2020
References
1. Guidelines for outpatient care in obstetrics and gynecology (in English). Ed. V.E. Radzinsky and others. 2nd ed., revised. and add. M.: GEOTAR-Media. 2014. 944 p.
2. Dobrokhotova Yu.E., Jobava E.M., Ragimova Z.E., Gerasimovich M. Yu. Hyperandrogenic syndrome in the practice of an obstetrician-gynecologist, dermatologist and endocrinologist: modern aspects of pathogenesis, diagnosis and therapy (in English). Moscow: GEOTAR-Media, 2009. 112 p. ISBN978–5–9704–1393–7.
3. PCOS: from reconsideration to new therapeutic strategies. Modern scientific data and clinical guidelines of the Ministry of Health of the Russian Federation 2015. Newsletter (in English) ed. by E.N. Andreeva, M.B. Khamoshina. M.: Editorial office of the journal Status Praesens. 2016. 28 p.
4. Kuznetsova I.V. The role of insulinsensitizers and calcium supplements with vitamin D3 in the complex therapy of polycystic ovary syndrome (in English). Endocrinology Problems. 2013; 59 (1): 49–56. DOI: 10.14341/probl201359149–56.
5. Dobrokhotova Yu.E., Lapina I. A., Chirvon T. G., Taranov V. V. New possibilities of integrative therapy for patients with polycystic ovary syndrome and disorders of carbohydrate and lipid metabolism. Results of a comparative study (in English). Mother and child. 2020; 3 (3): 169–173. DOI: 10.32364/2618–8430–2020–3–3–169–173.
6. Nordio M., Proietti E. The combined therapy with myo-inositol and Dchiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012; 16 (5): 575–81.
7. Gromova O.A., Torshin I. Yu., Limanova O.A. et al. Systematic analysis of the molecular physiological effects of myo-inositol – data from molecular biology, experimental and clinical medicine (in English). Effective pharmacotherapy in obstetrics and gynecology. 2013; 8: 37–43.
Review
For citations:
Khuraseva A.B., Svyatchenko K.S., Medvedev I.N. New opportunities in treatment of polycystic ovary syndrome. Medical alphabet. 2022;(4):27-30. (In Russ.) https://doi.org/10.33667/2078-5631-2022-4-27-30
Views:
249
Email this article 